MUMBAI, India, Nov. 2 -- Intellectual Property India has published a patent application (202611117045 A) filed by Dr. Navneet Verma; Aman Kushwaha; Dilip Kumar; Arvind Kumar; Pratiksha Rajesh Meshram; Dr. Ruchi Jain; Dr Prithu Pathak; Dr. P. Srikanth Reddy; Mukul Maurya; Dr. Swati Rathore; Nayyar Parvez; Dr. Amit Kumar Singh; Chinmaya Mahapatra; and Ms. Sapna Kumari on September 30, 2026, for Matrix-Type Transdermal Drug Delivery Patch Of Ketorolac Tromethamine And Method Of Preparation Thereof.
Inventors include Dr. Navneet Verma; Aman Kushwaha; Dilip Kumar; Arvind Kumar; Pratiksha Rajesh Meshram; Dr. Ruchi Jain; Dr Prithu Pathak; Dr. P. Srikanth Reddy; Mukul Maurya; Dr. Swati Rathore; Nayyar Parvez; Dr. Amit Kumar Singh; Chinmaya Mahapatra; and Ms. Sapna Kumari.
The application for the patent was published on October 30, 2026, under issue no. 44/2026.
Abstract: The present invention discloses a matrix-type transdermal drug delivery patch of ketorolac tromethamine comprising a solvent-cast polymer matrix of Eudragit RL 100 and hydroxypropyl methylcellulose K15M in a 3:1 weight ratio, dibutyl phthalate as plasticiser at 30 percent weight-in-weight of the polymer, and a terpene-based permeation enhancer selected from eucalyptus oil, d-limonene or menthol at 5 percent weight-in-volume, laminated between an aluminium-polyethylene terephthalate backing membrane and a silicone-coated release liner. The patch of 4 square centimetre area contains 10 milligrams of the drug and exhibits a thickness of 0.20 plus or minus 0.02 millimetres, folding endurance above 260 times, drug content uniformity of 98.5 percent, cumulative in vitro release of 84 percent at 24 hours following Higuchi diffusion kinetics, and an ex vivo transdermal flux across excised rat skin of 52.7 micrograms per square centimetre per hour representing a 1.9-fold enhancement over terpene-free control.
Disclaimer: Curated by HT Syndication.
